[1]王 翔,郭建明,崔世军,等.TAPAS血管内封闭导管紫杉醇浸润与紫杉醇药物涂层球囊治疗股腘动脉狭窄的对比[J].介入放射学杂志,2023,32(06):542-548.
 WANG Xiang,GUO Jianming,CUI Shijun,et al.Paclitaxel infiltration using TAPAS intravascular closed catheter versus paclitaxel drug-coated balloon for the treatment of femoropopliteal artery stenosis: a comparison study[J].journal interventional radiology,2023,32(06):542-548.
点击复制

TAPAS血管内封闭导管紫杉醇浸润与紫杉醇药物涂层球囊治疗股腘动脉狭窄的对比()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年06
页码:
542-548
栏目:
血管介入
出版日期:
2023-06-28

文章信息/Info

Title:
Paclitaxel infiltration using TAPAS intravascular closed catheter versus paclitaxel drug-coated balloon for the treatment of femoropopliteal artery stenosis: a comparison study
作者:
王 翔 郭建明 崔世军 齐立行 郭连瑞 谷涌泉
Author(s):
WANG Xiang GUO Jianming CUI Shijun QI Lixing GUO Lianrui GU Yongquan.
Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
关键词:
【关键词】 股腘动脉狭窄 紫杉醇 浸润 药物涂层球囊
文献标志码:
A
摘要:
【摘要】 目的 评价利用TAPAS血管内封闭导管的紫杉醇浸润在股腘动脉狭窄(FPAS)治疗中的应用价值。方法 设置紫杉醇涂层DCB组(组1)和TAPAS导管组(组2)。对2017年6月至2020年6月在首都医科大学宣武医院接受介入治疗的一批患者进行回顾性队列研究。随访终点事件为术后2年或出现不良事件。首要观察指标为患者/患肢一期通畅率和不良事件发生率。结果 共有73例患者符合入选标准。组1(n=55)、组2(n=18)间术前人口学、临床特点及术中造影诊断、预处理比较差异无统计学意义(均P>0.05)。截至随访终点,组1、组2患者/患肢间累积临床获益率(67.2%比88.9%)、一期通畅率(70.7%比77.8%)、非死亡不良事件率(18.3%比16.7%)、全因死亡率(3.6%比0%)比较差异无统计学意义(均P>0.05)。结论 对于FPAS患者,利用TAPAS血管内封闭导管的紫杉醇浸润能在术后2年内持续达到与紫杉醇DCB同等的治疗效果。

参考文献/References:

[1] Li H,Gui H,Yuan G,et al. Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients[J]. Scand J Clin Lab Invest, 2018, 78: 269- 274.
[2] Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population[J]. J Vasc Surg, 2014, 60: 686- 695.e2.
[3] 蒋米尔, 张培华. 临床血管外科学[M]. 4版. 北京:科学出版社, 2014:214.
[4] Kibrik P,Victory J,Patel R,et al. A real- world experience of drug- eluting and nondrug- eluting stents in lower extremity peripheral arterial disease[J]. J Vasc Surg, 2018, 68: e6.
[5] 王 鹏,陈晓伟,包 晗,等. 药物涂层球囊与金属裸支架治疗下肢动脉硬化闭塞症效果和安全性对比[J]. 介入放射学杂志, 2019, 28:1176- 1180.
[6] Schlager O, Gschwandtner ME, Willfort- Ehringer A, et al. Drug coated balloons in the superficial femoral artery[J]. J Cardiovasc Surg(Torino), 2018, 59: 60- 69.
[7] Aboyans V,Ricco JB,Bartelink MEL,et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)[J]. Eur Heart J, 2018,39:763- 816.
[8] Rogers JH, Lasala JM. Coronary artery dissection and perforation complicating percutaneous coronary intervention[J]. J Invasive Cardiol, 2004, 16: 493- 499.
[9] Mishra P,Singh U,Pandey CM,et al. Application of student’s t- test, analysis of variance, and covariance[J]. Ann Card Anaesth, 2019, 22: 407- 411.
[10] Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other[J]. Ann Math Stat, 1947, 18: 50- 60.
[11] Warner P. Testing association with Fisher’s exact test[J]. J Fam Plann Reprod Health Care, 2013, 39: 281- 284.
[12] Agresti A. Introduction to categorical data analysis[M]. New York: Wiley, 1996: 231- 236.
[13] Koletsi D,Pandis N. Survival analysis,part 2: Kaplan- Meier method and the log- rank test[J]. Am J Orthod Dentofacial Orthop, 2017, 152: 569- 571.
[14] 中华人民共和国国家卫生和计划生育委员会.中国临床戒烟指南(2015年版)[J]. 中华健康管理学杂志, 2016, 10:88- 95.
[15] 卫生部卫生统计信息中心. 国际疾病分类(ICD- 10)应用指导手册[M]. 北京:中国协和医科大学出版社, 2001:24.
[16] Kidney Disease Improving Global Outcomes(KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl, 2013, 3:1- 150.
[17] Unger T,Borghi C,Charchar F,et al.2020 International Society of Hypertension global hypertension practice guidelines[J]. Hyper- tension, 2020, 75: 1334- 1357.
[18] American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes- 2021[J]. Diabetes Care, 2021, 44: S15- S33.
[19] 中华医学会心血管病分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46:680- 694.
[20] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31:937- 950.
[21] Vestbo J,Hurd SS,Agusti AG,et al. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease: gold executive summary[J]. Am J Respir Crit Care Med, 2013, 187: 347- 365.
[22] Stoner MC,Calligaro KD,Chaer RA, et al. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease[J]. J Vasc Surg, 2016, 64: e1- e21.
[23] Rocha- Singh KJ,Zeller T,Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications[J]. Catheter Cardiovasc Interv, 2014, 83: E212- E220.
[24] Beard JD, Scott DJ, Evans JM, et al. Pulse- generated runoff: a new method of determining calf vessel patency[J]. Br J Surg, 1988, 75: 361- 363.
[25] Norgren L,Hiatt WR,Dormandy JA,et al. Inter- society consensus for the management of peripheral arterial disease(TASC Ⅱ)[J]. Eur J Vasc Endovasc Surg, 2007, 33 Suppl 1: S1- S75.
[26]国家心血管病专家委员会血管外科专业委员会下肢动脉疾病学组,中国医药教育协会血管外科专业委员会.股腘动脉闭塞症的诊断和治疗中国专家共识[J]. 中国循环杂志, 2022, 37:669- 676.
[27] 李艳奎,吴义生,张小明. TASC- D型下肢动脉硬化闭塞症腔内治疗现状[J].介入放射学杂志,2015,24:544- 547.
[28] 项以力,张温凯,杨 镛. 药物涂层球囊和无涂层球囊治疗股腘动脉缺血性疾病疗效及安全性Meta分析[J]. 介入放射学杂志, 2017, 26:500- 507.
[29] Lammer J,Zeller T,Hausegger KA,et al. Sustained benefit at 2 years for covered stents versus bare- metal stents in long SFA lesions: the VIASTAR trial[J]. Cardiovasc Intervent Radiol, 2015, 38: 25- 32.
[30] Bosiers M,Deloose K,Callaert J,et al. Superiority of stent- grafts for in- stent restenosis in the superficial femoral artery: twelve- month results from a multicenter randomized trial[J]. J Endovasc Ther, 2015, 22: 1- 10.
[31] Werner M,Paetzold A,Banning- Eichenseer U,et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self- expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry[J]. EuroIntervention, 2014, 10: 861- 868.
[32] Bausback Y,Wittig T,Schmidt A,et al. Drug- eluting stent versus drug- coated balloon revascularization in patients with femoro- popliteal arterial disease[J]. J Am Coll Cardiol, 2019, 73: 667- 679.
[33] 符伟国,岳嘉宁. 股腘动脉段病变支架内再狭窄的腔内治疗策略分析[J]. 中华外科杂志, 2016, 54:586- 590.
[34] Sobieszczyk P. In- stent restenosis after femoropopliteal interven- tions with drug- eluting stents: same but different?[J]. JACC Cardiovasc Interv, 2016, 9: 835- 837.
[35] 苏少飞,田玉峰,陈林宝,等. 抗凝联合抗血小板聚集治疗预防糖尿病下肢动脉硬化闭塞症支架植入后再狭窄的疗效分析[J]. 中国普通外科杂志, 2015, 24:823- 827.
[36] Tepe G,Schnorr B,Albrecht T,et al. Angioplasty of femoral- popliteal arteries with drug- coated balloons: 5- year follow- up of the THUNDER trial[J]. JACC Cardiovasc Interv, 2015, 8: 102- 108.
[37] Schneider PA,Laird JR,Tepe G, et al. Treatment effect of drug- coated balloons is durable to 3 years in the femoropopliteal arteries: long- term results of the IN.PACT SFA randomized trial[J]. Circ Cardiovasc Interv, 2018, 11: e005891.
[38] Krankenberg H, Tübler T, Ingwersen M, et al. Drug- coated balloon versus standard balloon for superficial femoral artery in- stent restenosis: the randomized femoral artery in- stent restenosis(FAIR) trial[J]. Circulation, 2015, 132: 2230- 2236.

相似文献/References:

[1]张文俐,杜 润,朱政斌,等. 药物洗脱球囊抑制下肢动脉狭窄性病变的实验研究[J].介入放射学杂志,2014,(05):423.
 ZHANG Wen- li,DU Run,ZHU Zheng- bin,et al. The inhibition effect of novel drug- eluting balloon on obstructive peripheral arterial disease of lower extremity: an experimental study in rabbit models[J].journal interventional radiology,2014,(06):423.
[2]解旭品,方 欣,黄昌拼,等.紫杉醇药物涂层球囊治疗股腘动脉支架内再狭窄18例 [J].介入放射学杂志,2017,(06):544.
 XIE Xupin,FANG Xin,HUANG Changpin,et al.Drug- coated balloon with paclitaxel for in- stent restenosis of femoral popliteal artery: initial experience in 18 patients[J].journal interventional radiology,2017,(06):544.

备注/Memo

备注/Memo:
(收稿日期:2023- 01- 08)
(本文编辑:谷 珂)
更新日期/Last Update: 2023-06-26